Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El peso de las enfermedades cardiovasculares

24 de septiembre de 2026 actualizado por: Kyla M. Lara-Breitinger, Mayo Clinic

El peso de las enfermedades cardiovasculares: un estudio piloto prospectivo de adultos obesos con enfermedades cardiovasculares evaluado en una nueva clínica cardiometabólica

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Descripción general del estudio

Estado

Activo, no reclutando

Tipo de estudio

De observación

Inscripción (Actual)

31

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic in Rochester

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients referred to the cardiometabolic clinic at Mayo Clinic Hospital in Rochester, MN will be recruited for participation.

Descripción

Inclusion Criteria:

  • BMI ≥30 kg/m2
  • At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  • Patients evaluated in the Cardiometabolic clinic
  • Willingness to complete questionnaires/surveys
  • Ability to complete monthly self-assessments at home

Exclusion Criteria:

  • BMI <30 kg/m2
  • Pregnancy or lactating women
  • Hemodynamically unstable CVD
  • Active malignancy
  • Autoimmune or systemic inflammatory diseases
  • Severe renal or hepatic failure
  • Being considered unsafe to participate as determined by the study physician
  • Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  • Patients with active psychosis, mania, or substance use disorders

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percent body weight loss
Periodo de tiempo: 12 months

Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss.

12 months
Change in Body Mass Index (BMI)
Periodo de tiempo: Baseline, 12 months

Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703

Baseline, 12 months
Change in visceral adiposity distribution
Periodo de tiempo: Baseline, 12 months

Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA).

Baseline, 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Blood Pressure
Periodo de tiempo: Baseline, 12 months

Measured in millimeters of mercury (mmHg)

Baseline, 12 months
Change in point of care glucose
Periodo de tiempo: Baseline, 12 months

Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing.

Baseline, 12 months
Change in quality of diet
Periodo de tiempo: Baseline, 12 months

Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet.

Baseline, 12 months
Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)
Periodo de tiempo: Baseline, 12 months

Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress.

Baseline, 12 months
Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)
Periodo de tiempo: Baseline, 12 months

Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus.

Baseline, 12 months
Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire
Periodo de tiempo: Baseline, 12 months

Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress.

Baseline, 12 months
Change in functional aerobic capacity (VO2 Max)
Periodo de tiempo: Baseline, 12 months

VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test

Baseline, 12 months
Change in artificial intelligence electrocardiogram (AI-ECG) age
Periodo de tiempo: Baseline, 12 months

AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs).

Baseline, 12 months
Change in E/e'
Periodo de tiempo: Baseline, 12 months

E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function.

Baseline, 12 months
Change in Peak Tricuspid Regurgitation (TR) Velocity
Periodo de tiempo: Baseline, 12 months

Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Right Atrial (RA) Pressure
Periodo de tiempo: Baseline, 12 months

RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Left Atrial (LA) volume index
Periodo de tiempo: Baseline, 12 months

LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in physical activity
Periodo de tiempo: Baseline, 12 months

Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in heart rate with detection of arrhythmia
Periodo de tiempo: Baseline, 12 months

Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in cardio fitness
Periodo de tiempo: Baseline, 12 months

Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in six-minute walk test
Periodo de tiempo: Baseline, 12 months

Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale
Periodo de tiempo: Baseline, 12 months

The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress.

Baseline, 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Kyla Lara-Breitinger, M.D., Mayo Clinic

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de abril de 2024

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

1 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

19 de septiembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

19 de septiembre de 2023

Publicado por primera vez (Actual)

26 de septiembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir